Overview
BTKi has become the standard treatment regimen for CLL/SLL，there is a lack of large-scale real-world studies on the use status and related influencing factors of BTK inhibitors. Therefore, we plan to conduct this multicenter retrospective cross-sectional study to understand the current situation of BTK inhibitor treatment for CLL/SLL patients in China and the related influencing factors, and to explore more suitable treatment patterns based on this.
Eligibility
Inclusion Criteria:
- Age ≥ 18 years;
- Patients with a confirmed diagnosis of CLL/SLL;
- Received BTK inhibitor treatment between February 2023 and February 2024.
Exclusion Criteria:
- Patients with other types of lymphoma;
- Cases deemed unsuitable for inclusion in this study by the investigators.